Erythropoietin in obstetrics.
Our objective was to discuss the role of erythropoietin in fetal erythropoiesis and to review its clinical uses in perinatal medicine. All relevant articles compiled through a MEDLINE search (years 1986-1997) were reviewed. Erythropoietin is essential for fetal erythropoiesis and is produced in response to hypoxia and anemia. Cord blood erythropoietin is purely fetal and reflects tissue oxygenation. It has been found to be increased in many complicated pregnancies with underlying fetal hypoxia. Erythropoietin could be used as a marker of fetal hypoxia because its concentration rises rapidly by increased production in response to hypoxia. Its measurement might enable more accurate timing of hypoxic injury. In addition, erythropoietin levels have been well correlated with perinatal brain damage and may facilitate treatment of high risk neonates. Erythropoietin has also been used successfully in anemia of prematurity, decreasing the transfusion requirement. However, studies are still needed to determine the optimal doses of erythropoietin and iron supplementations required for maximizing the red blood cell response. Erythropoietin has been examined as potential maternal therapy in various disorders during pregnancy. These include end-stage renal disease, severe antepartum iron deficiency anemia, and postpartum anemia. Erythropoietin has been found to be effective and well tolerated in these conditions. An additional promising use lies in the optimization of maternal red blood cell mass to allow autologous blood donation. This may be critical in cases where a large amount of bleeding might be anticipated, as with placenta previa. This would also minimize the donor transfusion-related hazards. Erythropoietin with its wide clinical applications could improve maternal and neonatal outcome.
Department of Obstetrics and Gynecology, Ottawa General Hospital, Canada.
M
M
Vora
A
A
Gruslin
D000740:Anemia / Q000503:physiopathology; D000818:Animals; D004920:Erythropoiesis / Q000502:physiology*; D004921:Erythropoietin / Q000502:physiology* / Q000627:therapeutic use; D005260:Female; D005315:Fetal Diseases / Q000503:physiopathology; D005311:Fetal Hypoxia / Q000503:physiopathology; D005333:Fetus / Q000502:physiology*; D006801:Humans; D011247:Pregnancy / Q000502:physiology*; D011994:Recombinant Proteins
D011994:Recombinant Proteins; D004921:Erythropoietin